Imunon Inc reports results for the quarter ended June 30 - Earnings Summary

• Imunon Inc IMNN.OQ reported a quarterly adjusted loss of $2.15​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-7.65. The mean expectation of five analysts for the quarter was for a loss of $4.74 per share. Wall Street expected results to range from $-8.40 to $-3.45 per share.

• Reported revenue was zero​; analysts expected zero.

• Imunon Inc's reported EPS for the quarter was a loss of $2.15​.

• The company reported a quarterly loss of $2.74 million.

• Imunon Inc shares had fallen by 23.3% this quarter and lost 35.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Imunon Inc is $135.00, about 93.2% above its last closing price of $9.20

This summary was machine generated from LSEG data August 5 at 02:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)